

Diseases & Treatments

Reference Number: F4752
Date of Response: 26/08/2022

Further to your Freedom of Information Act request, please find the Trust's response, in **blue bold text** below:

Royal Devon's Eastern FOI Office Response

- 1) In total, over the past 4 months, how many patients have been treated for the following diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa)?
- Rheumatoid arthritis - **217 patients**
 - Axial Spondyloarthritis – **30 patients**
 - Psoriatic arthritis - **44 patients**
 - Psoriasis - **125 patients**
 - Hidradenitis suppurativa – **10 patients**

Please see the Trust response to the remaining questions below (for the time period: 05/03/22 to 05/07/22).. However please Note:-

≤5.

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients and should not be published.

- 2) Of these five, how many of each received the following products:

	Rheumatoid arthritis	Axial Spondyloarthritis	Psoriatic arthritis	Psoriasis	Hidradenitis suppurativa
Adalimumab (Humira)	0	0	0	<5	0
Adalimumab Biosimilar	6	<5	<5	15	<5
Etanercept (Enbrel)	0	0	0	0	0
Etanercept Biosimilar	<5	0	0	0	0
Infliximab (Remicade)	0	0	0	0	0
Infliximab	<5	<5	0	0	0

biosimilar					
Golimumab (Simponi)	<5	<5	<5	<5	0
Tofacitinib (Xeljanz)	<5	0	0	0	0
Ustekinumab (Stelara)	0	0	<5	<5	0
Vedolizumab (Entyvio)	0	0	0	0	0
Filgotinib (Jyseleca)	0	0	0	0	0
Abatacept (Orencia)	0	0	0	0	0
Baricitinib (Olumiant)	0	0	0	0	0
Certolizumab Pegol (Cimzia)	<5	0	<5	<5	0
Rituximab (MabThera)	0	0	0	0	0
Rituximab Biosimilar	<5	0	0	0	0
Tocilizumab (RoActemra)	0	0	0	0	0
Sarilumab (Kevzara)	N/A	N/A	N/A	N/A	N/A
Apremilast (Otezla)	0	0	<5	<5	0
Secukinumab (Cosentyx)	<5	<5	0	<5	0
Isekizumab (Taltz)	0	0	0	<5	0
Guselkumab (Tremfya)	0	0	0	<5	0
Brodalumab (Kyntheum)	0	0	0	0	0
Risankizumab (Skyrizi)	0	0	0	<5	0
Tildrakizumab (Ilumetri)	0	0	0	0	0
Upadacitinib (Rinvoq)	<5	<5	<5	<5	0
Bimekizumab (Bimzelx)	0	0	0	0	0

3) Could you please provide the number of these patients that were treated within the gastro department (still split by disease and treatment).

	<u>Rheumatoid arthritis</u>	<u>Axial Spondyloarthritis</u>	<u>Psoriatic arthritis</u>	<u>Psoriasis</u>	<u>Hidradenitis suppurativa</u>
Adalimumab (Humira)	0	0	0	0	0
Adalimumab Biosimilar	0	0	0	0	0
Etanercept (Enbrel)	0	0	0	0	0
Etanercept Biosimilar	0	0	0	0	0
Infliximab (Remicade)	0	0	0	0	0

Infliximab biosimilar	0	0	0	0	0
Golimumab (Simponi)	0	0	0	0	0
Tofacitinib (Xeljanz)	0	0	0	0	0
Ustekinumab (Stelara)	0	0	0	0	0
Vedolizumab (Entyvio)	0	0	0	0	0
Filgotinib (Jyseleca)	0	0	0	0	0
Abatacept (Orencia)	0	0	0	0	0
Baricitinib (Olumiant)	0	0	0	0	0
Certolizumab Pegol (Cimzia)	0	0	0	0	0
Rituximab (MabThera)	0	0	0	0	0
Rituximab Biosimilar	0	0	0	0	0
Tocilizumab (RoActemra)	0	0	0	0	0
Sarilumab (Kevzara)	0	0	0	0	0
Apremilast (Otezla)	0	0	0	0	0
Secukinumab (Cosentyx)	0	0	0	0	0
Isekizumab (Taltz)	0	0	0	0	0
Guselkumab (Tremfya)	0	0	0	0	0
Brodalumab (Kyntheum)	0	0	0	0	0
Risankizumab (Skyrizi)	0	0	0	0	0
Tildrakizumab (Ilumetri)	0	0	0	0	0
Upadacitinib (Rinvoq)	0	0	0	0	0
Bimekizumab (Bimzelx)	0	0	0	0	0

4) Over the same time period, how many patients for each of the five diseases (Rheumatoid arthritis, Axial Spondyloarthritis, Psoriatic arthritis, Psoriasis, hidradenitis suppurativa) received the following treatments as their first ever biologic treatment?

	<u>Rheumatoid arthritis</u>	<u>Axial Spondyloarthritis</u>	<u>Psoriatic arthritis</u>	<u>Psoriasis</u>	<u>Hidradenitis suppurativa</u>
Adalimumab (Humira)	0	0	0	<5	0
Adalimumab Biosimilar	<5	<5	<5	13	<5
Etanercept (Enbrel)	0	0	0	0	0
Etanercept Biosimilar	<5	0	0	0	0

Infliximab (Remicade)	0	0	0	0	0
Infliximab biosimilar	0	<5	0	0	0
Golimumab (Simponi)	<5	<5	<5	0	0
Tofacitinib (Xeljanz)	<5	0	0	0	0
Ustekinumab (Stelara)	0	0	<5	<5	0
Vedolizumab (Entyvio)	0	0	0	0	0
Filgotinib (Jyseleca)	0	0	0	0	0
Abatacept (Orencia)	0	0	0	0	0
Baricitinib (Olumiant)	0	0	0	0	0
Certolizumab Pegol (Cimzia)	<5	0	<5	0	0
Rituximab (MabThera)	0	0	0	0	0
Rituximab Biosimilar	0	0	0	0	0
Tocilizumab (RoActemra)	0	0	0	0	0
Sarilumab (Kevzara)	0	0	0	0	0
Apremilast (Otezla)	0	0	<5	<5	0
Secukinumab (Cosentyx)	0	<5	0	0	0
Isekizumab (Taltz)	0	0	0	<5	0
Guselkumab (Tremfya)	0	0	0	<5	0
Brodalumab (Kyntheum)	0	0	0	0	0
Risankizumab (Skyrizi)	0	0	0	<5	0
Tildrakizumab (Ilumetri)	0	0	0	0	0
Upadacitinib (Rinvoq)	0	<5	0	0	0
Bimekizumab (Bimzelx)	0	0	0	0	0

For the time period: 05/03/22 to 05/07/22